BR112017020008A8 - Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele - Google Patents
Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da peleInfo
- Publication number
- BR112017020008A8 BR112017020008A8 BR112017020008A BR112017020008A BR112017020008A8 BR 112017020008 A8 BR112017020008 A8 BR 112017020008A8 BR 112017020008 A BR112017020008 A BR 112017020008A BR 112017020008 A BR112017020008 A BR 112017020008A BR 112017020008 A8 BR112017020008 A8 BR 112017020008A8
- Authority
- BR
- Brazil
- Prior art keywords
- skin diseases
- inflammatory skin
- fragments
- isolated peptides
- fibrinogen
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 title 1
- 102000008946 Fibrinogen Human genes 0.000 title 1
- 108010049003 Fibrinogen Proteins 0.000 title 1
- 229940012952 fibrinogen Drugs 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 208000017520 skin disease Diseases 0.000 title 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 2
- 201000004624 Dermatitis Diseases 0.000 abstract 2
- 206010000496 acne Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 229940106780 human fibrinogen Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305414 | 2015-03-20 | ||
| PCT/EP2016/056179 WO2016150926A1 (en) | 2015-03-20 | 2016-03-21 | Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017020008A2 BR112017020008A2 (pt) | 2018-06-19 |
| BR112017020008A8 true BR112017020008A8 (pt) | 2023-05-02 |
Family
ID=52807757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020008A BR112017020008A8 (pt) | 2015-03-20 | 2016-03-21 | Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10323078B2 (https=) |
| EP (1) | EP3270950B1 (https=) |
| JP (1) | JP6840086B2 (https=) |
| CN (1) | CN107636011B (https=) |
| AU (1) | AU2016236297B2 (https=) |
| BR (1) | BR112017020008A8 (https=) |
| CA (1) | CA2979812C (https=) |
| DK (1) | DK3270950T3 (https=) |
| ES (1) | ES2880795T3 (https=) |
| WO (1) | WO2016150926A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12502424B2 (en) | 2023-05-05 | 2025-12-23 | Sanofi Pasteur Inc. | Compositions for use in treatment of acne |
| CN117304303B (zh) * | 2023-07-14 | 2024-07-05 | 杭州恩和生物科技有限公司 | 纤连蛋白截短片段、组合物及用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69034085T2 (de) * | 1989-04-10 | 2004-05-27 | Helix BioMedix, Inc., Bothell | Lytsche und proliferative Peptide und deren Verwendung als Pharmaka und Phytopharmaka |
| US5639940A (en) * | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
| US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| CA2296792A1 (en) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| JP2003503425A (ja) * | 1999-06-30 | 2003-01-28 | リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 血栓性又は血栓塞栓性疾患のための診断的試験 |
| EP1411964A4 (en) * | 2001-07-06 | 2006-06-14 | Oregon Health Science Universi | PEPTIDES MODULATING BLOOD COAGULATION AND METHODS OF USE |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CA2523358A1 (en) * | 2003-04-23 | 2004-11-04 | Hansa Medical Ab | Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections |
| BRPI0617688A2 (pt) * | 2005-10-21 | 2011-06-07 | Hoffmann La Roche | método para expressão recombinante de um polipeptìdeo |
| US20130280820A1 (en) * | 2005-12-16 | 2013-10-24 | Schering Corporation | Biomarkers for psoriasis |
| WO2008019129A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
| EP2361930A3 (en) * | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| CN101618211A (zh) * | 2008-07-03 | 2010-01-06 | 珠海联邦制药股份有限公司 | 一种乙肝多肽疫苗及其应用 |
| CA2730030C (en) * | 2008-07-09 | 2019-09-03 | Profibrix Bv | Recombinant fibrinogen |
| EP2352998A4 (en) | 2008-11-07 | 2011-09-21 | Centocor Ortho Biotech Inc | MARKERS AND METHOD FOR THE STUDY AND TREATMENT OF LIGHT-SENSITIVELY LUPUS PATIENTS |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| EP2927690B1 (en) * | 2011-02-02 | 2022-10-26 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Anti-carbamylated protein antibodies and the risk for arthritis |
-
2016
- 2016-03-21 JP JP2017549280A patent/JP6840086B2/ja active Active
- 2016-03-21 US US15/559,984 patent/US10323078B2/en active Active
- 2016-03-21 ES ES16713796T patent/ES2880795T3/es active Active
- 2016-03-21 CA CA2979812A patent/CA2979812C/en active Active
- 2016-03-21 DK DK16713796.7T patent/DK3270950T3/da active
- 2016-03-21 BR BR112017020008A patent/BR112017020008A8/pt not_active IP Right Cessation
- 2016-03-21 EP EP16713796.7A patent/EP3270950B1/en active Active
- 2016-03-21 WO PCT/EP2016/056179 patent/WO2016150926A1/en not_active Ceased
- 2016-03-21 CN CN201680026130.XA patent/CN107636011B/zh active Active
- 2016-03-21 AU AU2016236297A patent/AU2016236297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016236297A1 (en) | 2017-09-28 |
| CA2979812C (en) | 2023-08-29 |
| EP3270950B1 (en) | 2021-04-21 |
| JP2018512844A (ja) | 2018-05-24 |
| JP6840086B2 (ja) | 2021-03-10 |
| AU2016236297B2 (en) | 2020-07-23 |
| CN107636011A (zh) | 2018-01-26 |
| EP3270950A1 (en) | 2018-01-24 |
| BR112017020008A2 (pt) | 2018-06-19 |
| CA2979812A1 (en) | 2016-09-29 |
| ES2880795T3 (es) | 2021-11-25 |
| US10323078B2 (en) | 2019-06-18 |
| CN107636011B (zh) | 2021-07-02 |
| DK3270950T3 (da) | 2021-06-07 |
| US20180105574A1 (en) | 2018-04-19 |
| WO2016150926A1 (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002094A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153) | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| BR112015011158A2 (pt) | triazolopirazina | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
| EP4378962A3 (en) | Anti-cancer fusion polypeptide | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| UA109278C2 (uk) | Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань | |
| BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
| BR112015014372A8 (pt) | inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas". | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112012009432A2 (pt) | anticorpo anti-hsv | |
| JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
| EA201790349A1 (ru) | Производные 6-алкинил-пиридина в качестве миметиков белка smac | |
| MY191980A (en) | Formulations containing an extract of echinacea and linoleic acid derivatives | |
| MX385925B (es) | Oritavancina de alta pureza y método para producir la misma. | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B25A | Requested transfer of rights approved |
Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; UNIVERSITE PARIS-SUD (FR) ; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE DE PARIS (FR) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2715 DE 17-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B25D | Requested change of name of applicant approved |
Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; UNIVERSITE PARIS-SUD (FR) ; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE PARIS CITE (FR) |